Thermo Fisher Scientific Inc. $TMO Shares Sold by Capital Research Global Investors

by · The Cerbat Gem

Capital Research Global Investors lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 7.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,914,901 shares of the medical research company’s stock after selling 247,761 shares during the period. Capital Research Global Investors owned about 0.78% of Thermo Fisher Scientific worth $1,689,072,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after acquiring an additional 288,296 shares in the last quarter. Capital World Investors grew its holdings in Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after acquiring an additional 706,572 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after buying an additional 26,425 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Thermo Fisher Scientific by 21.0% during the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock worth $2,874,069,000 after buying an additional 1,028,125 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $3,072,744,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TMO. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective for the company. Morgan Stanley restated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $613.67.

Get Our Latest Stock Report on Thermo Fisher Scientific

Thermo Fisher Scientific Trading Down 1.9%

NYSE TMO opened at $472.98 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $175.77 billion, a PE ratio of 26.00, a P/E/G ratio of 2.09 and a beta of 0.88. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The firm’s fifty day moving average is $479.94 and its two-hundred day moving average is $531.08.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).